Heart failure & cardiomyopathies
Clinical Performance and Quality Measures for Heart Failure Management in China: The China-Heart Failure Registry Study
Authors' conclusion
Despite significant improvements in the use of guideline-recommended testing and therapy, there remain major gaps in quality of care for patients hospitalized for HF in China that are generally larger than gaps observed in the United States.
Study context
- Population
- Patients hospitalised for Heart Failure (HF) in China, January 2017 to October 2020
- Participants
- 34,938 patients
- Exposure
- China-HF stage II vs China-HF stage I and US Get with The Guidelines-Heart Failure (GWTG-HF) registry
- Outcome
- Quality of care measures for HF management
Methodological detailsmulticentre, 113 hospitals, comparison with China-HF stage I and GWTG-HF registries
- Multicentre
- 113 hospitals
- Comparison with China-HF stage I and GWTG-HF registries
Main finding
As reported in the abstract
Quality of care measures
- Echocardiographic LV function assessed
- 93.7%
- Natriuretic peptide test performed
- 93.0%
- Eligible patients prescribed oral diuretics
- 78.2%
- Eligible patients prescribed renin-angiotensin-system inhibitors
- 78.7%
- Eligible patients prescribed beta-blockers
- 82.2%
- ICD implanted
- 3.9%
- Cardiac resynchronization devices implanted
- 14.6%
- Eligible patients discharged with spironolactone (higher than GWTG-HF)
- 87.8%
Observational data: associations, not effects.
Further findings
Length of hospitalisation
- Median length of hospitalisation, days
- 9 (6, 12)
Died or withdrew from treatment during hospitalisation
- Died or withdrew from treatment
- 938 (2.8%)
Original publication
Clinical Performance and Quality Measures for Heart Failure Management in China: The China-Heart Failure Registry Study. ESC Heart Fail. Published 12 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →